

Primary angiosarcoma of the oral cavity in a young adult

Bhagat Singh Lali¹ , Zachariah Chowdhury¹ , Monika Gupta² ,
Aseem Mishra² 

How to cite: Lali BS, Chowdhury Z, Gupta M, Mishra A. Primary angiosarcoma of the oral cavity in a young adult. *Autopsy Case Rep* [Internet]. xxxx xxx.-xxx.;00(00):e2020217. <https://doi.org/10.4322/acr.2020.217>

ABSTRACT

Angiosarcoma is a rare neoplasm, constituting only 2% of all the soft tissue tumors and most frequently involves the skin of the head and neck region in elderly males. They are extremely aggressive tumors with high rates of metastasis and poor outcomes. We report a unique case of angiosarcoma involving an unusual site – upper alveolus and maxilla in a young patient highlighting the diagnostic challenges in such a scenario. A 29 years old female presented with a non-healing wound of the oral cavity, which had progressed to the current maximum size of 6.4 cm within one month. Magnetic resonance imaging (MRI) scan revealed the involvement of maxilla up to the floor of the orbit and adjacent soft tissue. However, no distant metastasis was detected on Positron Emission Tomography (PET) scan. Biopsy of the lesion showed an irregular, highly pleomorphic, and mitotically active epithelioid soft tissue tumor conclusively diagnosed as angiosarcoma.

Keywords

Maxilla; Oral Ulcer; Rare Diseases; Sarcoma.

INTRODUCTION

Angiosarcomas are rare, aggressive malignant sarcomas arising from vascular endothelial cells. They constitute 2% of all the soft tissue sarcomas.¹ Tumors may arise at any anatomic location, but the skin of the head and neck and breast (arising in chronic lymphedema secondary to modified radical mastectomy) are frequently involved. The typical presentation is a scalp lesion in older Caucasian men.² Angiosarcomas are rare in children and young adults.³ They are rapidly progressing tumors that metastasize early and commonly recur locally even after surgical removal. These factors contribute to a reduced overall survival, with almost half of the patients dying within 15 months of diagnosis.^{4,5} We present the case of angiosarcoma

in a relatively young adult, which appeared at a very rare site, underlining the diagnostic conundrum and pointers towards an accurate diagnosis.

CASE REPORT

A 29-year-old female presented with a non-healing wound of the oral cavity, which she had had for 1 month. It was rapidly progressing in size. Apparently, she was asymptomatic 1 month earlier, when she developed an ulcer in the left upper alveolus with associated occasional minimal bleeding. She underwent alternative treatment, but the lesion

¹ Homi Bhabha Cancer Hospital, Department of Pathology, Varanasi, Uttar Pradesh, India

² Homi Bhabha Cancer Hospital, Department of Head and Neck Oncology, Varanasi, Uttar Pradesh, India



progressed in size. There was no significant family history, and she was a non-smoker, did not drink alcohol, and had no previous history of any chronic illness. On examination, a 4 × 4 cm proliferative lesion in the left upper alveolus was noted, involving the upper gingivobuccal sulcus and the palate (Figures 1A and 1B). A blue hue was discerned over the surface of the lesion, and it occasionally bled on touch. There was no cervical lymphadenopathy on palpation.

A magnetic resonance imaging (MRI) scan of the paranasal sinuses and the neck revealed a heterogeneously enhanced expansile soft tissue mass arising from the left upper alveolus, which

measured 6.4 × 5.2 × 5.6 cm (Figure 2A). A computed tomography (CT) scan showed that it had eroded the adjacent alveolar process and lateral wall of the maxilla, extending superiorly into the left maxillary sinus up to the orbital floor, the lateral pterygoid plate up to the skull base, and laterally into the subcutaneous plane. A positron emission tomography-computed tomography (PET-CT) scan revealed a primary avid maxillary tumor (Figure 2B); however, there was no metastatic lesion (Figure 2C).

A biopsy was performed from the mass; the histopathological examination revealed an irregular subepithelial tumor composed of proliferating vascular



Figure 1. A and B – Physical examination findings showing marked swelling in the left cheek with upper alveolus and palate involvement.




Figure 2. A – MRI T2 weighted image displaying the tumor extension; **B** – PET-CT scan demonstrating a fluorodeoxyglucose (FDG) avid tumor; **C** – Whole body positron emission tomography-computed tomography (PET-CT) scan without distant metastases.

channels filled with blood. The lining cells were highly pleomorphic and mostly epithelioid, exhibiting round-to-oval vesicular nuclei along with prominent nucleoli (Figures 3A and 3B). Areas of spindle cell proliferation were also identified, as well as large areas of hemorrhage, significant necrosis, and a high mitotic rate

(>20/10 hpf). On immunohistochemistry (IHC), the tumor cells were positive for CD31 (Figure 3C), FLI-1 (Figure 3D), CD34 (Figure 4A) and focally for AE1/AE3 (Figure 4B). The Ki-67 proliferation index was approximately 75-80% in the highest proliferation zone. These features pointed towards a diagnosis of angiosarcoma.




Figure 3. Photomicrographs of the tumor. **A** – subepithelial irregular vascular tumor (H&E, 10X); **B** – highly pleomorphic epithelioid tumor cells lining the vascular spaces (H&E, 40X); **C** – the tumor cells were diffusely positive for CD31 (10X); **D** – positive reaction to FLI-1 (10X); **E** – focally positive for CD34 (40X); **F** – focally positive for AE1/AE3 (10X).




Figure 4. Photomicrographs of the tumor. A- Immunohistochemical reaction focally positive for CD34 (40X); and for AE1/AE3 in B (10X).

Due to the involvement of the lateral pterygoid plate and the skull base, the tumor was inoperable. The patient was scheduled for palliative chemotherapy and radiation, but she did not turn up for the treatment.

DISCUSSION

Angiosarcoma is one of the rarest soft tissue tumors. It occurs most commonly in the skin or subcutaneous tissue of sun-exposed areas due to ultraviolet light exposure.^{1,2} Most of the cases are sporadic, and the potential causes of occurrence include radiation exposure, chemicals, or chronic lymphedema.⁴ History of trauma is cited as one of the causes, but authors believe it merely draws attention to a pre-existing lesion.¹ However, our patient did not have any history of exposure to these risk factors.

Angiosarcoma is seldom encountered in young individuals, and our patient was only 29 years old. The usual mean age of patients is more than 70 years. In the SEER database of 1,250 primary head and neck angiosarcoma, only 1.3% of patients were younger than 30 years.² Angiosarcoma is associated with congenital diseases, such as neurofibromatosis, bilateral retinoblastoma (Rb1 deletion), Klippel-Trenaunay syndrome, Aicardi syndrome, or xeroderma pigmentosum, which suggests a genetic association in young patients.⁶

Males are more commonly affected than females (2-3:1). Additionally, the site of involvement in our patient was very rare. In the SEER database, 93.5% of tumors were found to be cutaneous, and only 1.6% (n = 20) involved facial bones, buccal mucosa, or gums.^{1,2} Occasionally, metastatic tumors to the oral cavity have been reported from a primary tumor in the scalp or other locations.⁷

The clinical differential diagnosis in the present case included squamous cell carcinoma, hemangioma/vascular lesion, melanoma, or metastatic disease. Squamous cell carcinoma was included because it is the most common oral malignancy;⁸ vascular tumors due to the bluish hue over the lesion; and melanoma or metastatic disease due to the rapid growth of the lesion.

Rendering a diagnosis of angiosarcoma in an oral cavity lesion in a relatively young adult patient is a difficult proposition, due in part to (i) the rarity of the

entity in this age group; (ii) the uncommon site; and (iii) the significant clinical consequences of this diagnosis. The histomorphology can be variable, ranging from highly differentiated tumors resembling benign or intermediate-grade vascular lesions (e.g., hemangioma or hemangioendothelioma), to anaplastic lesions that are difficult to distinguish from a poorly differentiated carcinoma or other high-grade sarcomas.⁹

The typical picture is composed of anastomosing vascular spaces lined by atypical plump epithelioid-to-spindle cells with multilayering, and brisk mitosis and necrosis. In contrast to hemangiomas, the vascular channels in angiosarcoma seem to create their tissue planes, dissecting through the collagen and fascia; the tumor cells usually have larger hyperchromatic nuclei and often pile up along the lumens creating papillations.⁶ Hemangioendotheliomas can be excluded in the presence of extensive necrosis, marked cytologic atypia, epithelioid morphology, and brisk mitosis.³ An epithelioid morphology, a lack of obvious vasoformative foci, and frequent cytokeratin positivity may lead to an erroneous diagnosis of poorly differentiated metastatic (or primary) carcinoma.⁶ Pseudovascular adenoid or acantholytic squamous cell carcinoma can mimic angiosarcoma in the oral cavity on histology.¹⁰ Histopathological features, which are helpful in distinguishing epithelioid angiosarcoma from poorly differentiated metastatic/primary carcinoma, include occasional intracytoplasmic vacuoles with or without red blood cells, anastomosing vascular channels, and the lack of a desmoplastic reaction encountered in the former. Furthermore, strong immunoreactivity for vimentin, coupled with endothelial cell markers (Factor VIII, CD31, CD34) positivity, renders the diagnosis of metastatic carcinoma unlikely. The other differential diagnostic possibilities include malignant melanoma and epithelioid sarcoma.^{9,11} In addition to subtle histological differences, a panel of IHC markers, including positive staining for vascular markers and negative immunostaining for HMB-45, Melan-A, S 100, and CD45 readily exclude the diagnostic mimics.^{11,12} Notably, INI-1 was retained in our case, which helped to rule out an important mimicker—namely epithelioid sarcoma.¹³

Immunostaining with vimentin shows strong and diffuse positivity in angiosarcoma. The endothelial markers, CD31 and Factor VIII, are positive in nearly 100% of cases. CD34 positivity ranges from 40%

to 100%;¹² however, it is not a specific marker and is positive in very close morphological mimics, namely epithelioid sarcoma and solitary fibrous tumor. FLI1, a nuclear transcription factor, identifies more than 95% of vascular tumors regardless of the type and grade.¹⁴ However, it is also expressed in Ewing sarcoma, subsets of a wide range of mesenchymal tumors, subsets of high-grade lymphomas including lymphoblastic lymphomas and diffuse large B-cell lymphomas, and even subsets of carcinomas and melanomas. Thus, it has limited utility by itself owing to its low specificity.¹¹ Another nuclear transcription factor, ERG, is an exquisitely sensitive endothelial marker of vascular differentiation and is retained in even poorly differentiated angiosarcomas.¹³ However, ERG is also expressed in a subset of Ewing sarcomas (5-10%), prostatic adenocarcinomas, and a small subset of acute myeloid leukemia.¹¹ Among the vascular markers, CD31 is the most sensitive and specific antigen for endothelial differentiation; in combination with FLI-1, it helps the confident diagnosis of angiosarcomas.^{1,6,9} CD31 and FLI-1 positivity can be misleading, and a mistaken diagnosis of atypical fibroxanthoma is sometimes made; however, morphological details can help to avoid this.¹ Cytokeratin and epithelial membrane antigen positivity has been reported in up to 50% of epithelioid angiosarcomas focally, which was our finding as well.¹⁵ These markers could be potential diagnostic pitfalls and quandaries, so they should be used and interpreted in the appropriate clinicopathologic settings.

Surgery is the modality of choice for squamous cell carcinomas or sarcomas. Since the tumor was inoperable in our case due to the lateral pterygoid plate's involvement up to the skull base, palliative chemotherapy and radiation were the treatment options available. The definite histopathological diagnosis in such cases has major treatment implications. Squamous cell carcinomas are radiosensitive while sarcomas or melanomas do not respond to radiotherapy.¹⁶ Advanced malignant melanomas are tested for BRAF V600E mutations, and based on that, they are treated either with BRAF inhibitors and MEK inhibitors, or immunotherapy.¹⁷ In the case of metastatic carcinoma, the therapy is based on the primary tumor type. On the other hand, paclitaxel-based systemic chemotherapy is the preferred regimen for angiosarcomas. Tyrosine kinase inhibitors (TKI) have been used to inhibit the

vascular endothelial growth factor (VEGF) signaling pathway. Although a few studies have reported some promising results with TKI (e.g., sorafenib), there is no proven benefit.¹⁸ The other treatment options include chemotherapy with recombinant interleukin-2, or radiotherapy in a few cases, especially in the form of concurrent chemoradiation.¹⁹

However, the prognosis in angiosarcomas is dismal owing to early metastasis and multiple lesions. Up to 32% of patients have metastatic lesions at the time of diagnosis.²⁰ The 5-year overall survival and disease-free survival is 26.5% and 48.3%, respectively.² In multivariate analysis, age ≥ 70 years, tumor size of ≥ 5 cm, and the presence of metastasis at the time of diagnosis were the independent prognostic factors. Among them, the presence of metastasis is the most important since its presence increases the risk of overall and disease-specific death by 197% and 399%, respectively.²

To conclude, we present an exceedingly rare angiosarcoma case with respect to the unusual age at presentation and the site of involvement. Within the oral cavity, the differential diagnoses are varied and may be challenging in various scenarios. The pathology pearls must be borne in mind to surmount the diagnostic challenges. The treatment modalities also need to be tailored, considering the whole scenario. Nevertheless, the overall survival of patients is grim with these aggressive sarcomas.

ACKNOWLEDGEMENTS

The authors acknowledge the help of Dr. Shashikant Patne and the laboratory staff of our department of Pathology.

REFERENCES

1. Yang XJ, Zheng JW, Zhou Q, et al. Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients. *Int J Oral Maxillofac Surg.* 2010;39(6):568-72. <http://dx.doi.org/10.1016/j.ijom.2010.03.004>. PMID:20413272.
2. Lee KC, Chuang SK, Philipone EM, Peters SM. Characteristics and prognosis of primary head and neck angiosarcomas: a Surveillance, Epidemiology, and End Results program (SEER) analysis of 1250 cases. *Head Neck*

- Pathol. 2019;13(3):378-85. <http://dx.doi.org/10.1007/s12105-018-0978-3>. PMID:30357539.
3. Deyrup AT, Miettinen M, North PE, et al. Angiosarcomas arising in the viscera and soft tissue of children and young adults: a clinicopathologic study of 15 cases. *Am J Surg Pathol*. 2009;33(2):264-9. <http://dx.doi.org/10.1097/PAS.0b013e3181875a5f>. PMID:18987547.
 4. Nagata M, Yoshitake Y, Nakayama H, et al. Angiosarcoma of the oral cavity: a clinicopathological study and a review of the literature. *Int J Oral Maxillofac Surg*. 2014;43(8):917-23. <http://dx.doi.org/10.1016/j.ijom.2014.02.008>. PMID:24656496.
 5. Dettenborn T, Wermker K, Schulze HJ, Klein M, Schwipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study. *J Craniomaxillofac Surg*. 2014;42(8):1623-8. <http://dx.doi.org/10.1016/j.jcms.2014.05.002>. PMID:24962043.
 6. Goldblum JR, Folpe AL, Weiss SW. *Soft tissue tumors*. 6th ed. Philadelphia: Elsevier; 2014. p. 703-32: Malignant vascular tumors.
 7. Xu Y, Yang J, Mei K, Wu C, Wu Y. Angiosarcoma of the gingiva: metastasis from a primary tumor of the scalp. *Indian J Dermatol Venereol Leprol*. 2017;83(5):626. <http://dx.doi.org/10.4103/0378-6323.193608>. PMID:27852985.
 8. Bean MB, Liu Y, Jiang R, et al. Small cell and squamous cell carcinomas of the head and neck: comparing incidence and survival trends based on Surveillance, Epidemiology, and End Results (SEER) Data. *Oncologist*. 2019;24(12):1562-9. <http://dx.doi.org/10.1634/theoncologist.2018-0054>. PMID:31391295.
 9. Flucke U, Karanian M, Broek RWT, Thway K. Soft tissue special issue: perivascular and vascular tumors of the head and neck. *Head Neck Pathol*. 2020;14(1):21-32. <http://dx.doi.org/10.1007/s12105-020-01129-z>. PMID:31950476.
 10. Vidyavathi K, Harendra Kumar ML, Prasad CSBR, Deo RP. Pseudovascular adenoid squamous cell carcinoma of oral cavity: a mimicker of angiosarcoma. *J Oral Maxillofac Pathol*. 2012;16(2):288-90. <http://dx.doi.org/10.4103/0973-029X.99092>. PMID:22923907.
 11. Wei S, Henderson-Jackson E, Qian X, Bui MM. Soft tissue tumor immunohistochemistry update illustrative examples of diagnostic pearls to avoid pitfalls. *Arch Pathol Lab Med*. 2017;141(8):1072-91. <http://dx.doi.org/10.5858/arpa.2016-0417-RA>. PMID:28745570.
 12. Hart J, Mandavilli S. Epithelioid angiosarcoma: a brief diagnostic review and differential diagnosis. *Arch Pathol Lab Med*. 2011;135(2):268-72. PMID:21284449.
 13. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. *Vascular tumors*. In: WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: International Agency for Research on Cancer; 2013. p. 138-58.
 14. Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V, Dei Tos AP. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. *Mod Pathol*. 2004;17(5):547-52. <http://dx.doi.org/10.1038/modpathol.3800065>. PMID:15001993.
 15. Rao P, Lahat G, Arnold C, et al. Angiosarcoma: a tissue microarray study with diagnostic implications. *Am J Dermatopathol*. 2013;35(4):432-7. <http://dx.doi.org/10.1097/DAD.0b013e318271295a>. PMID:23689692.
 16. Watkinson J, Gilbert R. *Stell & Maran's textbook of head and neck surgery and oncology*. 5th ed. London: CRC Press; 2011. <http://dx.doi.org/10.1201/b13389>.
 17. Lima JPSN, Georgieva M, Haaland B, Lopes GL. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. *Cancer Med*. 2017;6(6):1143-53. <http://dx.doi.org/10.1002/cam4.1001>. PMID:28463413.
 18. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. *Am J Cancer Res*. 2019;9(11):2303-13. PMID:31815036.
 19. Suzuki G, Ogo E, Tanoue R, et al. Primary gingival angiosarcoma successfully treated by radiotherapy with concurrent intra-arterial chemotherapy. *Int J Clin Oncol*. 2011;16(4):439-43. <http://dx.doi.org/10.1007/s10147-010-0145-7>. PMID:21107878.
 20. Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: A 25-year single institution experience. *Am J Clin Oncol*. 2014;37(5):473-9. <http://dx.doi.org/10.1097/COC.0b013e31827e4e7b>. PMID:23428947.

This study carried out at the Homi Bhabha Cancer Hospital, Tata Memorial care, Varanasi, Uttar Pradesh, India.

Authors' contributions: Bhagat Singh Lali and Zachariah Chowdhury collected the information and prepared the manuscript. Monika Gupta and Aseem Mishra collected the clinical information and gave inputs on the treatment options. All the authors reviewed the final draft of the manuscript.

Ethics statement: This is a Case Report, and our Institute does not require Institute Ethics Committee approval for this kind of publication. Written informed consent has been taken from the patient for publication of this case report.

Conflict of interest: None.

Financial support: None.

Submitted on: May 5th, 2020

Accepted on: July 1st, 2020

Correspondence

Zachariah Chowdhury

Homi Bhabha Cancer Hospital, Department of Pathology

Old Loco Colony, Shivpurwa, 221010, Varanasi, Uttar Pradesh, India

Phone: +91 94 3503 1459

chowdhury.zachariah@gmail.com